Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 11, 2015, Pages 1141-1148

  Ananthakrishnan, A N ^a,b   Cagan, A ^c   Cai, T ^d   Gainer, V S ^c   Shaw, S Y ^a,b   Churchill, S ^e   Karlson, E W ^b,e   Murphy, S N ^a,b,e   Kohane, I ^b,e,f   Liao, K P ^b,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PARTNERS HEALTHCARE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOMODULATING AGENT; MERCAPTOPURINE; METHOTREXATE; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ASPERGILLOSIS; BACTEREMIA; CELLULITIS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; INFLUENZA; LUNG ABSCESS; MAJOR CLINICAL STUDY; MALE; MENINGITIS; OUTCOME ASSESSMENT; PNEUMONIA; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SEPSIS; STREPTOCOCCUS INFECTION; TUBERCULOSIS; ULCERATIVE COLITIS; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK; RISK FACTOR; STATISTICAL MODEL;

ADULT; DIABETES MELLITUS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929131406     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13195     Document Type: Article

References (34)

1. Ha CY, Katz S,. Clinical implications of ageing for the management of IBD. Nat Rev Gastroenterol Hepatol 2014; 11: 128-38.
2. Gisbert JP, Chaparro M,. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther 2014; 39: 459-77.
3. Ha CY,. Risks of infection among the older inflammatory bowel disease patients. Curr Treat Options Gastroenterol 2014; 12: 283-91.
4. Ananthakrishnan AN, McGinley EL, Binion DG,. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis 2009; 15: 182-9.
5. Shung DL, Abraham B, Sellin J, Hou JK., Medical and surgical complications of inflammatory bowel disease in the elderly: a systematic review. Dig Dis Sci 2014; doi: 10.1007/s10620-014-3462-2. [Epub ahead of print]
6. Baumgart DC, Sandborn WJ,. Crohn's disease. Lancet 2012; 380: 1590-605.
7. Ordas I, Eckmann L, Talamini M, et al,. Ulcerative colitis. Lancet 2012; 380: 1606-19.
8. Peyrin-Biroulet L, Lemann M,. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 870-9.
9. Afif W, Loftus EV Jr,. Safety profile of IBD therapeutics: infectious risks. Gastroenterol Clin North Am 2009; 38: 691-709.
10. Bewtra M, Lewis JD,. Safety profile of IBD: lymphoma risks. Gastroenterol Clin North Am 2009; 38: 669-89.
11. Fidder H, Schnitzler F, Ferrante M, et al,. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
12. Ananthakrishnan AN, McGinley EL,. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis 2013; 7: 107-12.
13. Bertoni AG, Saydah S, Brancati FL,. Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 2001; 24: 1044-9.
14. Casqueiro J, Casqueiro J, Alves C,. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab 2012; 16 (Suppl. 1): S27-36.
15. Joshi N, Caputo GM, Weitekamp MR, et al,. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341: 1906-12.
16. Muller LM, Gorter KJ, Hak E, et al,. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41: 281-8.
17. Geerlings SE, Brouwer EC, Van Kessel KC, et al,. Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 2000; 30: 995-1001.
18. Geerlings SE, Hoepelman AI,. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26: 259-65.
19. Ananthakrishnan AN, Cagan A, Cai T, et al,. Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2015; 13: 322-9.
20. Ananthakrishnan AN, Cagan A, Gainer VS, et al,. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis 2013; 19: 1921-7.
21. Ananthakrishnan AN, Cai T, Savova G, et al,. Improving case definition of Crohn's disease and ulcerative colitis in electronic medical records using natural language processing: a novel informatics approach. Inflamm Bowel Dis 2013; 19: 1411-20.
22. Charlson ME, Pompei P, Ales KL, et al,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
23. Lichtenstein GR, Feagan BG, Cohen RD, et al,. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012; 107: 1409-22.
24. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al,. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1051-63.
25. Wolfe F, Caplan L, Michaud K,. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628-34.
26. Greenberg JD, Reed G, Kremer JM, et al,. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010; 69: 380-6.
27. Curtis JR, Patkar N, Xie A, et al,. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56: 1125-33.
28. Peleg AY, Weerarathna T, McCarthy JS, et al,. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007; 23: 3-13.
29. Grijalva CG, Chen L, Delzell E, et al,. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-9.
30. Toruner M, Loftus EV Jr, Harmsen WS, et al,. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36.
31. Rahier JF,. Prevention and management of infectious complications in IBD. Dig Dis 2012; 30: 408-14.
32. Rahier JF, Magro F, Abreu C, et al,. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8: 443-68.
33. Warman JI, Korelitz BI, Fleisher MR, et al,. Cumulative experience with short-and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003; 37: 220-5.
34. Present DH, Meltzer SJ, Krumholz MP, et al,. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med 1989; 111: 641-9.